Donanemab and Lecanemab for Mild Alzheimer's Disease: Clinical Efficacy, Safety, and Implementation Challenges
This review examines two disease-modifying monoclonal antibodies—lecanemab and donanemab—that target amyloid-beta pathology in early-stage Alzheimer's disease, showing modest cognitive decline reductions (27-29%) over 18-76 months in clinical trials. Key challenges addressed include variable efficacy across demographic groups, amyloid-related imaging abnormalities, cost barriers, and the need for more inclusive research and personalized treatment approaches.
Sources
- MED — Wed Aug 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Thu Dec 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Mon Sep 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Wed Sep 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Sun Jul 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Mon Dec 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Wed Apr 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
- MED — Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Read full article (translated)
Afișăm titlu + rezumat scurt în limita dreptului de autor; textul integral e la sursă.